世界の生体外毒性/毒性テスト市場動向及び予測（～2018）...市場調査レポートについてご紹介

Table Of Contents

1 Introduction (Page No. – 21)
1.1 Objectives Of The Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Market Scope
1.6 Research Methodology
1.6.1 Market Size Estimation & Data Triangulation
1.6.2 Key Data Points From Secondary Sources
1.6.3 Key Data Points From Primary Sources
1.6.4 Assumptions

2 Executive Summary (Page No. – 34)

3 Premium Insights (Page No. – 40)
3.1 Market Size
3.2 Market Dynamics
3.3 In-Vitro Toxicity Testing Market Size Snapshot
3.4 In-Vitro Toxicity Testing, Geographic Analysis By Industry
3.5 In-Vitro Toxicity Testing Market Size, By Technology
3.6 In-Vitro Toxicity Testing Market Size, By Method
3.7 In-Vitro Toxicity Testing Market, By Application

4 Market Overview (Page No. – 47)
4.1 Introduction
4.2 Market Segmentation
4.3 Market Dynamics
4.3.1 Drivers
4.3.1.1 Dearth Of Publicly Accessible Databases to Facilitate The Use Of In Vitro Test Methods
4.3.1.2 New and Promising Technologies to Propel Market
4.3.1.3 Technological Advancements and Shifting Focus to Innovative Approaches Of 3d Cell Cultures Are Driving The Cell Culture Technology Market
4.3.1.4 Opposition to Animal Testing Will Help Shift The Focus to In Vitro Testing
4.3.2 Restraints
4.3.2.1 Technological Disadvantages Associated With In Vitro Tests Limit Their Use
4.3.2.2 In Vitro Models Cannot Detect Autoimmunity and Immunostimulation
4.3.2.3 Predictive Ability Of In Vitro Testing Leads to Decreasing Adoption Of These Tests
4.3.3 Opportunities
4.3.3.1 The Toxicology In The 21st Century (Tox21) Program
4.3.3.2 Increasing Drug Discovery and Innovation and Modernization in The Market
4.3.3.3 Growing Demand For In Vitro Toxicology in The European Market
4.3.4 Threats
4.3.4.1 Reluctance Of Regulatory Authorities to Consider Alternate Methods For Proving Safety and Efficacy
4.4 Burning Issues
4.4.1 Validation Of New In Vitro Methods
4.4.2 Differences in Opinion Between The U.S. and Eu Regulatory Authorities
4.5 Winning Imperatives
4.5.1 3d Human Hepatocyte Models to Boost The In Vitro Testing Market

5 By Industry (Page No. – 60)
5.1 Introduction
5.2 Diagnostics
5.2.1 Diagnostics, By Type
5.2.1.1 Forensics
5.2.1.2 Drug Abuse & Workplace Drug Testing
5.2.2 Diagnostics, By Sample
5.2.2.1 Urine Screening
5.2.2.2 Alcohol Screening
5.2.2.3 Oral Fluid Screening
5.2.2.4 Hair Screening
5.2.2.5 Others
5.3 Cosmetics & Household Products
5.4 Pharmaceutical Industry
5.5 Chemicals Industry
5.6 Food Industry

6 By Technology (Page No. – 86)
6.1 Introduction
6.1.1 Cell Culture Technology
6.1.1.1 Primary Monolayer and Three-Dimensional Cell Cultures
6.1.2 High Throughput Technologies
6.1.2.1 High Throughput Toxicity Testing
6.1.2.2 The Epa Toxcast Program
6.1.3 Molecular Imaging Technologies
6.1.3.1 Molecular Imaging Technologies
6.1.3.2 High Content Imaging Technologies
6.1.4 Omics Technologies
6.1.4.1 Genomics
6.1.4.2 Toxicogenomics
6.1.4.3 Proteomics
6.1.4.4 Metabolomics

7 By Application (Page No. – 108)
7.1 Introduction
7.2 Systemic Toxicity
7.3 Dermal Toxicity
7.4 Ocular Toxicity
7.5 Endocrine Disruption (Reproductive/Developmental Toxicity)
7.6 Others (Admet, Organ-Specific Toxicity, Drug-Drug Interactions, Target/Pathway Assays, & Ecotoxicity)
7.6.1 Admet (Pharmacokinetics & Metabolism Testing)
7.6.2 Organ-Specific Toxicity
7.6.3 Drug-Drug Interactions
7.6.4 Target/Pathway Assays
7.6.5 Ecotoxicity

8 By Method (Page No. – 124)
8.1 Introduction
8.2 Cellular Assays
8.3 Biochemical Assays
8.4 In Silico Methods
8.5 Ex Vivo Models

9 Geographic Analysis (Page No. – 137)
9.1 Introduction
9.2 Europe
9.3 North America
9.4 Asia
9.5 Rest Of The World (ROW)

10 Competitive Landscape (Page No. – 168)
10.1 Introduction
10.2 Competitive Landscape, 2011-March 2014
10.3 New Product Launches
10.4 Mergers & Acquisitions
10.5 Agreements, Partnerships & Collaborations
10.6 Expansions
10.7 Other Developments

11 Company Profiles (Business Overview, Products & Services, Key Strategy, Recent Developments, Mnm View)* (Page No. – 191)
11.1 Agilent Technologies, Inc.
11.2 Alere, Inc.
11.3 Bio-Rad Laboratories, Inc.
11.4 Bioreliance, Inc. (A Subsidiary Of Sigma-Aldrich Corporation)
11.5 Catalent
11.6 Charles River Laboratories International, Inc.
11.7 Covance, Inc.
11.8 Cyprotex
11.9 Eurofins Scientific
11.1 GE Healthcare
11.11 Life Technologies Corporation (Thermo Fisher Scientific)
11.12 Quest Diagnostics

*Details On Products & Services, Key Strategy, & Recent Developments Might Not Be Captured in Case Of Unlisted Companies.